[Etiopathogenesis of the polycystic ovary syndrome].
D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D000293:Adolescent; D000308:Adrenocortical Hyperfunction / Q000150:complications; D000328:Adult; D000568:Amenorrhea / Q000209:etiology; D000728:Androgens / Q000096:biosynthesis; D004967:Estrogens / Q000096:biosynthesis; D005260:Female; D006628:Hirsutism / Q000209:etiology; D006801:Humans; D007247:Infertility, Female / Q000209:etiology; D009030:Mosaicism; D009765:Obesity / Q000209:etiology; D010900:Pituitary Diseases / Q000150:complications; D011085:Polycystic Ovary Syndrome / Q000209:etiology* / Q000235:genetics / Q000652:urine; D011276:Pregnanediol / Q000652:urine; D011279:Pregnanetriol / Q000652:urine; D012729:Sex Chromosome Aberrations; D014770:Virilism / Q000209:etiology
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D000728:Androgens; D004967:Estrogens; D011279:Pregnanetriol; D011276:Pregnanediol
Considerazioni sulla etiopatogenesi della sindrome da ovaio policistico.